2024 Q4 Form 10-K Financial Statement

#000141057824002100 Filed on December 17, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2024
Revenue $1.197M $3.431M
YoY Change 34.28% -74.33%
Cost Of Revenue $512.5K $2.415M
YoY Change -22.35% -69.18%
Gross Profit $684.1K $1.017M
YoY Change 196.03% -81.62%
Gross Profit Margin 57.17% 29.63%
Selling, General & Admin $2.633M $11.45M
YoY Change -14.63% -10.22%
% of Gross Profit 384.9% 1125.79%
Research & Development $1.015M $3.594M
YoY Change 8.46% -3.78%
% of Gross Profit 148.37% 353.41%
Depreciation & Amortization $58.58K $696.4K
YoY Change -80.4% -48.88%
% of Gross Profit 8.56% 68.49%
Operating Expenses $3.648M $15.04M
YoY Change -9.25% -8.77%
Operating Profit -$2.964M -$14.02M
YoY Change -21.77% 28.04%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$20.15K -$8.877K
YoY Change 48.86% -1482.71%
Pretax Income -$2.669M -$7.088M
YoY Change 136.11% -29.28%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$2.639M -$6.993M
YoY Change 138.84% -29.7%
Net Earnings / Revenue -220.57% -203.78%
Basic Earnings Per Share -$0.56 -$1.82
Diluted Earnings Per Share -$0.56 -$1.82
COMMON SHARES
Basic Shares Outstanding 52.29M 10.30M 3.966M
Diluted Shares Outstanding 31.52M 3.966M

Balance Sheet

Concept 2024 Q4 2024 Q3 2024
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $10.10M $6.431M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory $468.6K $438.6K
Prepaid Expenses
Receivables $911.5K $362.0K
Other Receivables
Total Short-Term Assets $11.28M $8.048M
YoY Change 145.66% -0.97%
LONG-TERM ASSETS
Property, Plant & Equipment $638.5K $553.2K
YoY Change 18.39% -34.0%
Goodwill
YoY Change
Intangibles $2.699M $2.699M
YoY Change 0.0% 0.0%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $4.695M $4.741M
YoY Change -11.81% -14.18%
TOTAL ASSETS
Total Short-Term Assets $11.28M $8.048M
Total Long-Term Assets $4.695M $4.741M
Total Assets $15.97M $12.79M
YoY Change 61.11% -6.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.234M $1.166M
YoY Change 21.31% 8.73%
Accrued Expenses
YoY Change
Deferred Revenue $217.2K $58.79K
YoY Change 301.99% -23.09%
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.387M $2.398M
YoY Change -7.78% -15.72%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.387M $2.398M
Total Long-Term Liabilities
Total Liabilities $3.421M $3.821M
YoY Change -40.86% -56.48%
SHAREHOLDERS EQUITY
Retained Earnings -$327.2M -$309.7M
YoY Change 7.77% 2.39%
Common Stock $340.0M $318.8M
YoY Change 10.43% 3.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $12.75M $9.143M
YoY Change
Total Liabilities & Shareholders Equity $15.97M $12.79M
YoY Change 61.11% -6.32%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2024
OPERATING ACTIVITIES
Net Income -$2.639M -$6.993M
YoY Change 138.84% -29.7%
Depreciation, Depletion And Amortization $58.58K $696.4K
YoY Change -80.4% -48.88%
Cash From Operating Activities -$3.326M -$13.71M
YoY Change -11.49% 120.52%
INVESTING ACTIVITIES
Capital Expenditures $116.9K $407.9K
YoY Change 419.97%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$116.9K -$407.9K
YoY Change -62.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $13.40M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.306M 13.40M
YoY Change -18078.74%
NET CHANGE
Cash From Operating Activities -3.326M -13.71M
Cash From Investing Activities -116.9K -407.9K
Cash From Financing Activities 6.306M 13.40M
Net Change In Cash 2.863M -720.7K
YoY Change -175.49% -90.15%
FREE CASH FLOW
Cash From Operating Activities -$3.326M -$13.71M
Capital Expenditures $116.9K $407.9K
Free Cash Flow -$3.443M -$14.12M
YoY Change 124.25%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024 dei Entity Central Index Key
EntityCentralIndexKey
0000744452
CY2024 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2024 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2024 dei Entity Registrant Name
EntityRegistrantName
APPLIED DNA SCIENCES INC
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
682926
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10311885
CY2024Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.05
CY2024Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.05
CY2024Q3 apdn Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2024Q3 apdn Fair Value Liabilities Level2 To Level1 Transfers Amount1
FairValueLiabilitiesLevel2ToLevel1TransfersAmount1
0
CY2024Q3 apdn Fair Value Liabilities Level1 To Level2 Transfers Amount1
FairValueLiabilitiesLevel1ToLevel2TransfersAmount1
0
CY2024 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2024 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2024 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2024 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2024 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-6280000
CY2024 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants
CY2024 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2024 dei Amendment Flag
AmendmentFlag
false
CY2024 dei Document Type
DocumentType
10-K
CY2024 dei Document Annual Report
DocumentAnnualReport
true
CY2024 dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
CY2024 dei Document Transition Report
DocumentTransitionReport
false
CY2024 dei Entity File Number
EntityFileNumber
001-36745
CY2024 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
59-2262718
CY2024 dei Entity Address Address Line1
EntityAddressAddressLine1
50 Health Sciences Drive
CY2024 dei Entity Address City Or Town
EntityAddressCityOrTown
Stony Brook
CY2024 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2024 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
11790
CY2024 dei City Area Code
CityAreaCode
631
CY2024 dei Local Phone Number
LocalPhoneNumber
240-8800
CY2024 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19856778
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
385698
CY2024 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Concentrations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents, restricted cash and trade receivables. The Company places its cash and cash equivalents with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit. As of September 30, 2024, the Company had cash and cash equivalents of approximately $6.1 million in excess of the FDIC insurance limit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company’s revenues earned from the sale of products and services for the fiscal year ended September 30, 2024 included an aggregate of 26% and 17%, from one customer within the MDx Testing Services segment and one customer within the Therapeutic DNA Production Services segment, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company’s revenues earned from the sale of products and services for the fiscal year ended September 30, 2023 included an aggregate of 65% and 14%, respectively from two customers within the MDx Testing Services segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">At September 30, 2024, four customers accounted for 59% of the Company’s accounts receivable. At September 30, 2023, three customers accounted for 60% of the Company’s accounts receivable.</p>
CY2024Q3 us-gaap Time Deposits At Or Above Fdic Insurance Limit
TimeDepositsAtOrAboveFDICInsuranceLimit
6100000
CY2024 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3593750
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3735078
CY2024 us-gaap Advertising Expense
AdvertisingExpense
124036
CY2023 us-gaap Advertising Expense
AdvertisingExpense
185115
CY2024 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
CY2023 apdn Offering Costs Incurred
OfferingCostsIncurred
633198
CY2024 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2024 dei Trading Symbol
TradingSymbol
APDN
CY2024 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2024 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2024 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024 dei Entity Small Business
EntitySmallBusiness
true
CY2024 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2024 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2024 dei Entity Shell Company
EntityShellCompany
false
CY2024Q1 dei Entity Public Float
EntityPublicFloat
5700000
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
52294359
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024 dei Auditor Firm
AuditorFirmId
688
CY2024 dei Auditor Name
AuditorName
Marcum LLP
CY2024 dei Auditor Location
AuditorLocation
Melville, NY
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6431095
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7151800
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
75000
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
75000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
362013
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
255502
CY2024Q3 us-gaap Inventory Net
InventoryNet
438592
CY2023Q3 us-gaap Inventory Net
InventoryNet
330027
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
815970
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
389241
CY2024Q3 us-gaap Assets Current
AssetsCurrent
8047670
CY2023Q3 us-gaap Assets Current
AssetsCurrent
8126570
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
553233
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
838270
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2698975
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2698975
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
739162
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1237762
CY2024Q3 us-gaap Assets
Assets
12789040
CY2023Q3 us-gaap Assets
Assets
13651577
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1793427
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2270388
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
545912
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
498598
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
58785
CY2024 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2024Q3 apdn Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
76435
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2398124
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2845421
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
31467
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
31467
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
194000
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
194000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
193249
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
739162
CY2024Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
684115
CY2023Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
684115
CY2024Q3 apdn Common Warrant Liability Noncurrent
CommonWarrantLiabilityNoncurrent
320000
CY2023Q3 apdn Common Warrant Liability Noncurrent
CommonWarrantLiabilityNoncurrent
4285000
CY2024Q3 us-gaap Liabilities
Liabilities
3820955
CY2023Q3 us-gaap Liabilities
Liabilities
8779165
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10311885
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
682926
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
10314
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
683
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
318805058
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
307397623
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-309672755
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-302447147
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
9142617
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
4951159
CY2024Q3 us-gaap Minority Interest
MinorityInterest
-174532
CY2023Q3 us-gaap Minority Interest
MinorityInterest
-78747
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8968085
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4872412
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12789040
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13651577
CY2024 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3431420
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
13367443
CY2024 us-gaap Cost Of Revenue
CostOfRevenue
2414541
CY2023 us-gaap Cost Of Revenue
CostOfRevenue
7834011
CY2024 us-gaap Gross Profit
GrossProfit
1016879
CY2023 us-gaap Gross Profit
GrossProfit
5533432
CY2024 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11447894
CY2023 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12751644
CY2024 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3593750
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3735078
CY2024 us-gaap Operating Expenses
OperatingExpenses
15041644
CY2023 us-gaap Operating Expenses
OperatingExpenses
16486722
CY2024 us-gaap Operating Income Loss
OperatingIncomeLoss
-14024765
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-10953290
CY2024 us-gaap Investment Income Interest
InvestmentIncomeInterest
176301
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
75332
CY2024 apdn Transaction Cost Allocated To Warrant Liabilities
TransactionCostAllocatedToWarrantLiabilities
-633198
CY2024 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-9430000
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-854400
CY2024 apdn Unrealized Loss On Change In Fair Value Of Warrants
UnrealizedLossOnChangeInFairValueOfWarrants
-394000
CY2024 apdn Loss On Issuance Of Warrants
LossOnIssuanceOfWarrants
1633767
CY2024 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8877
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
642
CY2024 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7088306
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10022916
CY2024 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024 us-gaap Profit Loss
ProfitLoss
-7088306
CY2023 us-gaap Profit Loss
ProfitLoss
-10022916
CY2024 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-95785
CY2023 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-75857
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-6992521
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-9947059
CY2024 apdn Deemed Dividend Related To Warrant Modifications
DeemedDividendRelatedToWarrantModifications
233087
CY2024 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7225608
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9947059
CY2024 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.82
CY2024 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.82
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-15.21
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-15.21
CY2024 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3966026
CY2024 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3966026
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
653771
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
653771
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
12908939
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1033889
CY2023 us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
952500
CY2023 us-gaap Profit Loss
ProfitLoss
-10022916
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4872412
CY2024 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-572293
CY2024 apdn Shares And Pre Funded Warrants Issued In Public Offering
SharesAndPreFundedWarrantsIssuedInPublicOffering
10525063
CY2024 apdn Stock Issued During Period Value Upon Exercise Of Warrants
StockIssuedDuringPeriodValueUponExerciseOfWarrants
4940
CY2024 us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
17125
CY2024 us-gaap Profit Loss
ProfitLoss
-7088306
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8968085
CY2024 us-gaap Profit Loss
ProfitLoss
-7088306
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
81008
CY2023Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
212079
CY2024Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
221250
CY2023Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
19859
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
136334
CY2023Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
98089
CY2023 us-gaap Profit Loss
ProfitLoss
-10022916
CY2024 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
696425
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1362249
CY2023 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
6083
CY2023 apdn Write Off Of Property And Equipment
WriteOffOfPropertyAndEquipment
62000
CY2024 apdn Earnout Expense Asset Purchase Agreement
EarnoutExpenseAssetPurchaseAgreement
17125
CY2024 apdn Unrealized Gain On Change In Fair Value Of Warrants
UnrealizedGainOnChangeInFairValueOfWarrants
9430000
CY2023 apdn Unrealized Gain On Change In Fair Value Of Warrants
UnrealizedGainOnChangeInFairValueOfWarrants
854400
CY2024 apdn Unrealized Loss On Change In Fair Value Of Warrants
UnrealizedLossOnChangeInFairValueOfWarrants
-394000
CY2024 apdn Registered Direct Offering Costs
RegisteredDirectOfferingCosts
633198
CY2024 apdn Loss On Issuance Of Warrants
LossOnIssuanceOfWarrants
1633767
CY2024 us-gaap Share Based Compensation
ShareBasedCompensation
572293
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
1033889
CY2023 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-239043
CY2024 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
106511
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3051083
CY2024 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
108565
CY2023 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-272217
CY2024 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
426729
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-767812
CY2024 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-480444
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1351363
CY2024 apdn Increase Decrease In Deferred Revenues
IncreaseDecreaseInDeferredRevenues
-17650
CY2023 apdn Increase Decrease In Deferred Revenues
IncreaseDecreaseInDeferredRevenues
-293122
CY2024 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13711397
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6217677
CY2023 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1062360
CY2023 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
45000
CY2024 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
407904
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
78448
CY2024 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-407904
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1095808
CY2024 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
394
CY2024 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13398202
CY2024 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13398596
CY2024 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-720705
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7313485
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7901800
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15215285
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7181095
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7901800
CY2023 us-gaap Stock Issued1
StockIssued1
952500
CY2024 apdn Deemed Dividend Warrant Modifications
DeemedDividendWarrantModifications
233087
CY2023 us-gaap Liabilities Assumed1
LiabilitiesAssumed1
684115
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1545916
CY2024 apdn Property Plant And Equipment Acquired And Included In Accounts Payable
PropertyPlantAndEquipmentAcquiredAndIncludedInAccountsPayable
3484
CY2024Q3 us-gaap Inventory Net
InventoryNet
438592
CY2023Q3 us-gaap Inventory Net
InventoryNet
330027
CY2024 apdn Number Of Primary Markets That Use Company S Technologies
NumberOfPrimaryMarketsThatUseCompanySTechnologies
3
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-309672755
CY2024 us-gaap Profit Loss
ProfitLoss
-7088306
CY2024 apdn Net Cash Used In Operating Activities
NetCashUsedInOperatingActivities
13711397
CY2024Q4 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
5800000
CY2024Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10100000
CY2024 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The preparation of the financial statements in conformity with Accounting Principles Generally Accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The most significant estimates include revenue recognition, recoverability of long-lived assets, including the values assigned to intangible assets, fair value calculations for warrants, contingencies, and management’s anticipated liquidity. Management reviews its estimates on a regular basis and the effects of any material revisions are reflected in the consolidated financial statements in the period they are deemed necessary. Accordingly, actual results could differ from those estimates.</p>
CY2023Q3 apdn Threshold Period For Assets Yield On Net Sales Revenue To Cover Cost Of Acquisition
ThresholdPeriodForAssetsYieldOnNetSalesRevenueToCoverCostOfAcquisition
P10Y
CY2024 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3431420
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
13367443
CY2024 us-gaap Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination
ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination
17650
CY2023 us-gaap Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination
ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination
293122
CY2024 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
40035
CY2023 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
345480
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6431095
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7151800
CY2024Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
750000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
750000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7181095
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7901800
CY2024 apdn Contract With Customer Asset Current Period Increase Decrease Total
ContractWithCustomerAssetCurrentPeriodIncreaseDecreaseTotal
106511
CY2023 apdn Contract With Customer Asset Current Period Increase Decrease Total
ContractWithCustomerAssetCurrentPeriodIncreaseDecreaseTotal
-2812042
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
75000
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4662243
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4250471
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4109010
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3412201
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
553233
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
838270
CY2024 us-gaap Depreciation
Depreciation
696425
CY2023 us-gaap Depreciation
Depreciation
1362249
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1165727
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1072161
CY2024Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
509281
CY2023Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1138235
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
118419
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
59992
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1793427
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2270388
CY2024Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1
CY2024Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1
CY2024Q2 apdn Class Of Warrant Or Right Number Of Shares Called By Each Pre Funded Warrant
ClassOfWarrantOrRightNumberOfSharesCalledByEachPreFundedWarrant
1
CY2024Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
12.18
CY2024Q1 apdn Threshold Period For Filing Of Registration Statement On Form S3 From Date Of Purchase Agreements
ThresholdPeriodForFilingOfRegistrationStatementOnFormS3FromDateOfPurchaseAgreements
P45D
CY2024Q1 apdn Threshold Period To Use Commercially Reasonable Efforts To Cause Registration Statement To Become Effective From Closing Of Purchase Agreements
ThresholdPeriodToUseCommerciallyReasonableEffortsToCauseRegistrationStatementToBecomeEffectiveFromClosingOfPurchaseAgreements
P90D
CY2024 apdn Registered Direct Offering Costs
RegisteredDirectOfferingCosts
633198
CY2024Q1 apdn Class Of Warrant Or Right Sale Price Per Share
ClassOfWarrantOrRightSalePricePerShare
12.18
CY2024Q1 apdn Number Of Warrants Held By Other Investors Not Participate In Offering
NumberOfWarrantsHeldByOtherInvestorsNotParticipateInOffering
2904
CY2024Q1 apdn Class Of Warrant Or Right Sale Price Per Share
ClassOfWarrantOrRightSalePricePerShare
12.18
CY2024 apdn Adjustments To Additional Paid In Capital Deemed Dividend Warrant Repricing
AdjustmentsToAdditionalPaidInCapitalDeemedDividendWarrantRepricing
155330
CY2023Q4 apdn Adjustments To Additional Paid In Capital Deemed Dividend Warrant Repricing
AdjustmentsToAdditionalPaidInCapitalDeemedDividendWarrantRepricing
6397939
CY2024 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
4501
CY2024 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
64397
CY2024 apdn Capitalized Transaction Costs For Asset Purchase Transaction Written Off
CapitalizedTransactionCostsForAssetPurchaseTransactionWrittenOff
217000
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
25.8
CY2024 apdn Change In Deemed Dividend Related To Warrant Modification
ChangeInDeemedDividendRelatedToWarrantModification
77757
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
261029
CY2023Q3 apdn Weighted Average Price Per Share Warrant Outstanding
WeightedAveragePricePerShareWarrantOutstanding
3.5
CY2024 apdn Class Of Warrant Or Right Granted
ClassOfWarrantOrRightGranted
28305629
CY2024 apdn Weighted Average Price Per Share Warrant Granted
WeightedAveragePricePerShareWarrantGranted
1.64
CY2024 apdn Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
8626796
CY2024 apdn Weighted Average Price Per Share Warrant Exercised
WeightedAveragePricePerShareWarrantExercised
-0.002
CY2024 apdn Class Of Warrant Or Right Forfeitures And Expirations
ClassOfWarrantOrRightForfeituresAndExpirations
191719
CY2024 apdn Weighted Average Price Per Share Warrant Cancelled Or Expired
WeightedAveragePricePerShareWarrantCancelledOrExpired
-56.98
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
19748143
CY2024Q3 apdn Weighted Average Price Per Share Warrant Outstanding
WeightedAveragePricePerShareWarrantOutstanding
2.78
CY2024 apdn Share Price Two
SharePriceTwo
1.27
CY2024 apdn Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price Two
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceTwo
1.27
CY2024 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.57
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0364
CY2024 us-gaap Share Based Compensation
ShareBasedCompensation
572293
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
1033889
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
268476
CY2024 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P2Y5M4D
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.2
CY2024 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
5874000
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-3249000
CY2024 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
5874000
CY2023 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
-3249000
CY2024 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
417000
CY2023 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-1161000
CY2024 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
417000
CY2023 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
-1161000
CY2024 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-11000
CY2023 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-121000
CY2024 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-6280000
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
4531000
CY2024 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 apdn Effective Income Tax Rate Reconciliation Federal Benefit
EffectiveIncomeTaxRateReconciliationFederalBenefit
0.01
CY2024 apdn Effective Income Tax Rate Reconciliation Federal Benefit
EffectiveIncomeTaxRateReconciliationFederalBenefit
0.01
CY2024 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.1019
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0956
CY2024 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.0204
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.0176
CY2024 apdn Effective Income Tax Rate Reconciliation Permanent Differences Related Warrants Percent
EffectiveIncomeTaxRateReconciliationPermanentDifferencesRelatedWarrantsPercent
0.2033
CY2023 apdn Effective Income Tax Rate Reconciliation Permanent Differences Related Warrants Percent
EffectiveIncomeTaxRateReconciliationPermanentDifferencesRelatedWarrantsPercent
0.018
CY2024 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.0249
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.0197
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0128
CY2024 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.0243
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.0993
CY2024 apdn Effective Income Tax Reconciliation Adjustment For Prior Years Net Operating Losses
EffectiveIncomeTaxReconciliationAdjustmentForPriorYearsNetOperatingLosses
-1.3765
CY2024 apdn Effective Income Tax Rate Reconciliation Change In Deferred Tax Rate Percent
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxRatePercent
-0.0081
CY2023 apdn Effective Income Tax Rate Reconciliation Change In Deferred Tax Rate Percent
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxRatePercent
0.0167
CY2024 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.8982
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.4545
CY2024 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2024Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1309000
CY2023Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
993000
CY2024Q3 apdn Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
333000
CY2023Q3 apdn Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
440000
CY2024Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
18463000
CY2023Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
25250000
CY2024Q3 apdn Deferred Tax Assets Impairment Intangible Assets
DeferredTaxAssetsImpairmentIntangibleAssets
222000
CY2023Q3 apdn Deferred Tax Assets Impairment Intangible Assets
DeferredTaxAssetsImpairmentIntangibleAssets
227000
CY2024Q3 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1386000
CY2023Q3 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
726000
CY2024Q3 apdn Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
200000
CY2023Q3 apdn Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
342000
CY2024Q3 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
2885000
CY2023Q3 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
3060000
CY2024Q3 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
141000
CY2023Q3 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
324000
CY2024Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
24939000
CY2023Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
31362000
CY2024Q3 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
684000
CY2023Q3 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
684000
CY2024Q3 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
200000
CY2023Q3 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
342000
CY2024Q3 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
884000
CY2023Q3 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1026000
CY2024Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
24739000
CY2023Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
31020000
CY2024Q3 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
684000
CY2023Q3 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
684000
CY2024Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
71634000
CY2024Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
49169000
CY2024Q3 apdn Increase Decrease In Deferred Tax Assets Operating Loss Carryforwards Federal
IncreaseDecreaseInDeferredTaxAssetsOperatingLossCarryforwardsFederal
-40477000
CY2024Q3 apdn Increase Decrease In Deferred Tax Assets Operating Loss Carryforwards Domestic
IncreaseDecreaseInDeferredTaxAssetsOperatingLossCarryforwardsDomestic
-16849000
CY2024Q3 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2369000
CY2024Q3 apdn Deferred Tax Assets Tax Credit Carryforwards State Investment
DeferredTaxAssetsTaxCreditCarryforwardsStateInvestment
469000
CY2024 apdn Area Of Property Under Operating Lease
AreaOfPropertyUnderOperatingLease
30000
CY2023Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
CY2023Q1 apdn Area Of Laboratory Space
AreaOfLaboratorySpace
2500
CY2017Q4 apdn Lease For Satellite Testing
LeaseForSatelliteTesting
1108
CY2017Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2017Q4 apdn Base Rent During Initial Lease Term
BaseRentDuringInitialLeaseTerm
6500
CY2024 us-gaap Operating Lease Expense
OperatingLeaseExpense
722332
CY2023 us-gaap Operating Lease Expense
OperatingLeaseExpense
663513
CY2024 us-gaap Operating Lease Cost
OperatingLeaseCost
597670
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
560841
CY2024 us-gaap Short Term Lease Cost
ShortTermLeaseCost
124662
CY2023 us-gaap Short Term Lease Cost
ShortTermLeaseCost
102672
CY2024 us-gaap Lease Cost
LeaseCost
722332
CY2023 us-gaap Lease Cost
LeaseCost
663513
CY2024 us-gaap Operating Lease Payments
OperatingLeasePayments
586334
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y3M18D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.091
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
586334
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
195445
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
781779
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
42615
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
739164
CY2024 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2024 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3431420
CY2024 us-gaap Gross Profit
GrossProfit
1016879
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
13367443
CY2023 us-gaap Gross Profit
GrossProfit
5533432
CY2024 us-gaap Investment Income Interest
InvestmentIncomeInterest
176301
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
75332
CY2024 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-9430000
CY2024 apdn Unrealized Loss On Change In Fair Value Of Warrants
UnrealizedLossOnChangeInFairValueOfWarrants
-394000
CY2024 apdn Registered Direct Offering Cost
RegisteredDirectOfferingCost
633198
CY2023 apdn Registered Direct Offering Cost
RegisteredDirectOfferingCost
-854400
CY2024 apdn Loss On Issuance Of Warrants
LossOnIssuanceOfWarrants
1633767
CY2024 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8877
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
642
CY2024 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7088306
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10022916
CY2024 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3431420
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
13367443
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
4285000
CY2024 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
5071000
CY2024 apdn Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Warrant Modification Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantModificationGainLossIncludedInEarnings
394000
CY2024 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
9430000
CY2024Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
320000

Files In Submission

Name View Source Status
0001410578-24-002100-index-headers.html Edgar Link pending
0001410578-24-002100-index.html Edgar Link pending
0001410578-24-002100.txt Edgar Link pending
0001410578-24-002100-xbrl.zip Edgar Link pending
apdn-20240930.xsd Edgar Link pending
apdn-20240930x10k.htm Edgar Link pending
apdn-20240930xex19d1.htm Edgar Link pending
apdn-20240930xex21d1.htm Edgar Link pending
apdn-20240930xex23d1.htm Edgar Link pending
apdn-20240930xex31d1.htm Edgar Link pending
apdn-20240930xex31d2.htm Edgar Link pending
apdn-20240930xex32d1.htm Edgar Link pending
apdn-20240930xex32d2.htm Edgar Link pending
apdn-20240930xex97d1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
apdn-20240930_cal.xml Edgar Link unprocessable
apdn-20240930_def.xml Edgar Link unprocessable
apdn-20240930_lab.xml Edgar Link unprocessable
apdn-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
apdn-20240930x10k_htm.xml Edgar Link completed
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending